Clinical Roundup

Rural hospital system demonstrates clinical benefits of universal hereditary cancer testing in breast cancer

Results from a collaborative study on universal hereditary cancer genetic testing in all patients with breast cancer in a rural population in the Annals of Surgical Oncology. Conducted by Invitae in collaboration with The Outer Banks Hospital in North Carolina from 2019 to 2022, the study analyzed the implementation of universal hereditary cancer genetic testing in all patients with breast cancer, as recommended by the American Society of Breast Surgeons guidelines in 2019. 
Clinical Roundup

Kisqali reduced the risk of cancer recurrence while maintaining QOL in phase III study

Patient-reported outcomes data from the phase III NATALEE trial, presented at the European Society for Medical Oncology Virtual Plenary, show that a broad population of patients with stage 2 and 3 hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer maintained health-related quality of life during treatment with Kisqali (ribociclib) plus endocrine therapy.